Share on StockTwits
 

Cubist Pharmaceuticals (NASDAQ:CBST) CEO Michael W. Bonney sold 3,112 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were sold at an average price of $75.60, for a total value of $235,267.20. Following the completion of the sale, the chief executive officer now directly owns 168,485 shares in the company, valued at approximately $12,737,466. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on CBST shares. Analysts at Zacks reiterated a “neutral” rating on shares of Cubist Pharmaceuticals in a research note on Friday, January 24th. They now have a $79.00 price target on the stock. Separately, analysts at Credit Suisse reiterated an “outperform” rating on shares of Cubist Pharmaceuticals in a research note on Friday, January 24th. They now have a $77.00 price target on the stock. Finally, analysts at Aegis raised their price target on shares of Cubist Pharmaceuticals from $70.00 to $85.00 in a research note on Friday, January 24th. They now have a “buy” rating on the stock. Five equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $70.94.

Shares of Cubist Pharmaceuticals (NASDAQ:CBST) traded up 1.17% during mid-day trading on Friday, hitting $78.70. The stock had a trading volume of 638,642 shares. Cubist Pharmaceuticals has a one year low of $40.44 and a one year high of $77.90. The stock has a 50-day moving average of $72.68 and a 200-day moving average of $66.36. The company’s market cap is $5.857 billion.

Cubist Pharmaceuticals (NASDAQ:CBST) last announced its earnings results on Wednesday, January 22nd. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.30. The company had revenue of $299.70 million for the quarter, compared to the consensus estimate of $285.47 million. During the same quarter in the previous year, the company posted $0.51 earnings per share. The company’s revenue for the quarter was up 21.9% on a year-over-year basis. On average, analysts predict that Cubist Pharmaceuticals will post $0.52 earnings per share for the current fiscal year.

Cubist Pharmaceuticals, Inc (NASDAQ:CBST) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.